Fig. 4: Effectiveness of prior infection vaccination, and hybrid immunity on SARS-CoV-2 infection among residents of Connecticut Department of Correction facilities between June 15, 2021, and May 10, 2022, by documented exposure status. | Nature Communications

Fig. 4: Effectiveness of prior infection vaccination, and hybrid immunity on SARS-CoV-2 infection among residents of Connecticut Department of Correction facilities between June 15, 2021, and May 10, 2022, by documented exposure status.

From: Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population

Fig. 4: Effectiveness of prior infection vaccination, and hybrid immunity on SARS-CoV-2 infection among residents of Connecticut Department of Correction facilities between June 15, 2021, and May 10, 2022, by documented exposure status.The alternative text for this image may have been generated using AI.

Forest plot depicting the association between prior infection, vaccination, and hybrid immunity and the risk of SARS-CoV-2 infection by facility exposure type. Residents were classified as having a cell exposure event (green) the day their cellmate tested positive, having a cellblock exposure event (brown) the day a resident of their cellblock but not cell tested positive, and having an event without documented exposure (navy) if no one in their cellblock tested positive. Cell exposure events that occurred within 14 days following a prior cell exposure event were excluded. Cellblock exposure events and events without documented exposure that occurred in the 14 days following a cellblock or cell exposure event were excluded. Associations were examined using Cox Proportional Hazard Models stratified by cellblock with robust standard errors. Each model was adjusted for age, date of exposure, race, room size, and model (a) was adjusted for vaccination status and model (b) was adjusted for prior infection status. Model (c) was limited to residents with hybrid immunity or residents without a record of prior infection or vaccination. Prior infection was defined as a recorded positive SARS-CoV-2 test ≥90 days before the event and vaccination was defined as the receipt of ≥1 dose before the event. Hybrid immunity was defined as a record of both a prior infection and ≥1 vaccine dose. Boxes indicate estimated hazard ratio (HR) point values and whiskers indicate 95% confidence intervals (Delta: n = 17,024 no exposure events, 5616 cellblock exposure events, 264 cell exposure events; Omicron: n = 13,464 no exposure events, 5980 cellblock exposure events, 702 cell exposure events). The ratio of HRs refer to the p-value comparing the HR following cellblock or cell exposure events to the HR following events without documented exposures, estimated using two-sided z-tests. No multiple testing adjustment was performed. Unadjusted results in Supplement Table 7.

Back to article page